Compare American Electric Power Company Inc (AEP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Electric Power Company Inc vs State Street SPDR S&P Biotech ETF — how do they compare? American Electric Power Company Inc trades at $136.44 (market cap $74.83B), while State Street SPDR S&P Biotech ETF trades at $162. The key difference: American Electric Power Company Inc pays a 2.76% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| AEP | XBI | |
|---|---|---|
Market Cap | $74.83B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $138.69 | $163.87 |
52-Week Low | $103.96 | $84.71 |
Enterprise Value | $126.09B | — |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $137.53, down 0.71% on the day, with strong analyst support (64% buy ratings) and a $142.82 consensus price target. The stock shows bullish technical momentum with recent earnings beats and robust revenue growth, climbing from $19.7B in 2024 to $21.9B in 2025. AEP benefits from AI-driven electricity demand and a $78B capital plan for grid expansion.
Outlook remains positive given AEP's strategic positioning in energy infrastructure, though risks include high capital expenditures and debt levels. The current valuation at 20.12x P/E appears reasonable for a utility with stable earnings growth and dividend payments, supporting a constructive view for long-term investors.
XBI trades at $160.81, up 0.22% for the day, with a bullish technical signal driven by moving averages but overbought RSI readings. The ETF has surged approximately 17% over the past month, fueled by biotech sector momentum, AI-driven drug discovery advancements, and robust M&A activity. Analyst consensus remains neutral with a single hold rating, while recent news highlights strong performance relative to broader healthcare ETFs.
Outlook: XBI offers exposure to biotech growth catalysts including M&A and innovation, but high volatility and overbought conditions pose near-term risks. Long-term potential hinges on sector stability and pipeline successes, though investors face elevated beta and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
